“The prolyl oligopeptidase inhibitor KYP‑2047 is not readily bioavailable to bloodstream form trypanosomes and human myelocytic leukemia cells”, Journal of Pharmaceutical Negative Results, vol. 6, no. 1, pp. 7–10, Jan. 2015, Accessed: May 14, 2026. [Online]. Available: https://mail.pnrjournal.com/index.php/home/article/view/84